Executives And Founders Of Uber, Facebook And Apple Are Bullish On This Wellness App — You Can Coinvest At $1.15 Per Share

La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Aura Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Aura Biosciences..

Aura Biosciences (NASDAQ:AURA) Azioni, Catena delle Opzioni

Aura Biosciences

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Aura Biosciences Inc

Aura Energy Ltd

Aura Fat Projects Acquisition Corp Ordinary Shares - Class A

Aura Fat Projects Acquisition Corp

Aura Fat Projects Acquisition Corp Units (1 Ord Class A & 1 War)

Aura Fat Projects Acquisition Corp Warrants(31/03/2027)

Aura Minerals Inc

Aura Systems Inc

AuraSource Inc

AURANIA RESOURCES ORD by Aurania Resources, Ltd.

Aurania Resources Ltd

Aurania Resources Ltd Warrants (21/10/2026)

Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) reported quarterly earnings of $0.97 per share which missed the analyst consensus estimate of $1.07 by 9.35 percent. This is a 13.39 percent decrease over earnings of $1.12 per share from the same period last year. The company reported quarterly sales of $773.70 million which beat the analyst consensus estimate of $747.51 million by 3.50 percent. This is a 4.46 percent increase over sales of $740.70 million the same period last year.

News

Spectrum Brands Holdings Q4 Adj $0.97 Misses $1.07 Estimate, Sales $773.70M Beat $747.51M Estimate

Earnings

BABA

Alibaba Q2 Cloud Intelligence Group Revenue $4.22B (+7% YoY), International Digital Commerce $4.51B (+29% YoY), Cainiao Smart Logistics Revenue $3.51B (+8% YoY)

The company plans to issue a special one-time dividend of 5 million shares of its Class B Common Stock to all holders of its Class A Common Stock and the Series C Convertible Preferred Stock on an as-converted basis. The record date for the Distribution is November 29, 2024.

Dividends

GPUS

Hyperscale Data Declares Special Dividend Of Class B Common Stock

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $135 price target.

Price Target

Reiteration

Analyst Ratings

BPMC

HC Wainwright & Co. Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Alibaba Group Holding Q2 Adj EPADS $2.15, Sales $33.70B Beat $33.47B Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) with a Buy and maintains $8 price target.

IMAB

HC Wainwright & Co. Reiterates Buy on I-MAB, Maintains $8 Price Target

Needham analyst Charles Shi maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy and lowers the price target from $240 to $225.

AMAT

Needham Maintains Buy on Applied Mat, Lowers Price Target to $225

<a href="https://www.bloomberg.com/news/articles/2024-11-15/alibaba-is-said-to-consider-offering-5-billion-of-bonds?sref=y3YMCJ4e" title="https://www.bloomberg.com/news/articles/2024-11-15/alibaba-is-said-to-consider-offering-5-billion-of-bonds?sref=y3YMCJ4e">https://www.bloomberg.com/news/articles/2024-11-15/alibaba-is-said-to-consider-offering-5-billion-of-bonds?sref=y3YMCJ4e</a>

Bonds

Offerings

Markets

Bloomberg Reported Earlier, Alibaba Is Said To Consider Offering $5B Of Bonds

HC Wainwright &amp; Co. analyst Robert Burns reiterates ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and maintains $36 price target.

AVBP

HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $36 Price Target

On Thursday, Nov. 14, U.S. markets ended lower after Fed Chair Jerome Powell dampened hopes for an interest rate cut, citing steady economic growth, a strong job market, and persistent inflation. Traders reduced bets on a December cut, leading to declines in the Dow, S&amp;P 500, and Nasdaq.
Powell&#8217;s remarks followed data showing a rise in producer prices for October, slightly higher than expected.
Related: <a target="_blank" href="https://www.benzinga.com/news/treasuries/24/11/41993899/powells-hawkish-remarks-shake-markets-stocks-fall-dollar-rockets-bitcoin-dips" rel="noreferrer noopener">Powell&#8217;s Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips</a>
Economic data showed that U.S. jobless claims fell by 4,000 to 217,000 for the week ending Nov. 9, beating estimates of 223,000. Producer prices increased by 0.2% in October, matching market expectations after a revised 0.1% rise in September.
The majority of S&amp;P 500 sectors fell, led by consumer discretionary, industrials, and healthcare. However, tech and energy stocks ended higher.
The Dow Jones Industrial Average was down 0.47% and closed at 43,750.86, the S&amp;P 500 declined 0.50% to 5,949.17, and the Nasdaq Composite slid 0.64% to finish at 19,107.65.
Asia Markets Today
<ul>
<li>On Friday, Japan&#8217;s Nikkei 225 declined 0.35% and ended the session at 38,637.50, led by gains in the Warehousing, Shipbuilding, and Trading sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 rose 0.74% and ended the day at 8,285.20, led by gains in the Utilities, Gold, and Financials sectors.</li>
<li>India Markets were closed for the Guru Nanak Jayanti holiday.</li>
<li>China&#8217;s Shanghai Composite declined 1.45% to close at 3,330.73, and the Shenzhen CSI 300 fell 1.75%, finishing the day at 3,968.83.</li>
<li>Hong Kong&#8217;s Hang Seng slipped 0.09% and closed the session at 19,426.34.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was down 0.23%.</li>
<li>Germany&#8217;s DAX gained 0.14%.</li>
<li>France&#8217;s CAC fell0.04%.</li>
<li>UK&#8217;s FTSE 100 index traded higher by 0.02%.</li>
<li>European stocks were mixed after weak U.K. growth data, higher French inflation, and hawkish Fed remarks.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 1.35% at $67.78/bbl, and Brent was down 1.28% at $71.63/bbl.</li>
<li>Oil prices declined, heading for a weekly loss amid concerns over weakening Chinese demand and fewer anticipated U.S. rate cuts. Lower refinery output and slowing factory growth in China added pressure.</li>
<li>Natural Gas declined 2.44% to $2.717.</li>
<li>Gold was trading higher by 0.04% at $2,573.80, Silver gained 0.16% to $30.610, and Copper rose 1.6% to $4.1420.</li>
</ul>
US Futures at 05:30 AM ET
Dow futures decreased 0.44%, S&amp;P 500 futures were down 0.63%, and Nasdaq 100 futures fell 0.88%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index declined 0.15% to 106.51, USD/JPY was down 0.60% at 155.30, and USD/AUD slid 0.25% to 1.5453.</li>
<li>The U.S. dollar hit near one-year highs after Fed Chair Powell&#8217;s hawkish comments boosted Treasury yields, pressuring equities. The dollar&#8217;s surge weighed on the euro, gold, and oil prices.</li>
</ul>
Image via Pexels

Asia

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Mixed; Fed's Hawkish Comments Boost Dollar - Global Markets Today While US Slept

HC Wainwright &amp; Co. analyst Robert Burns reiterates Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) with a Buy and maintains $33 price target.

CRGX

HC Wainwright & Co. Reiterates Buy on Cargo Therapeutics, Maintains $33 Price Target

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) with a Neutral and maintains $3 price target.

HC Wainwright & Co. Reiterates Neutral on Kodiak Sciences, Maintains $3 Price Target

HC Wainwright &amp; Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) with a Buy and maintains $9 price target.

CRBU

HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) with a Buy and maintains $7 price target.

DMAC

HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $7 Price Target

Needham analyst Joshua Reilly reiterates Digimarc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMRC#NASDAQ">DMRC</a>) with a Buy and maintains $40 price target.

DMRC

Needham Reiterates Buy on Digimarc, Maintains $40 Price Target

References to "30+ delinquency rate" are to over-30 day loan delinquencies as a percentage of period-end loan receivables.&nbsp;

Synchrony Financial October 30+ Delinquency Rate 4.9% Vs. 4.6% Last Year; Net Charge-off Rate 6.2% Vs. 5.4% Prior Year - Filing

Digihost Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGHI#NASDAQ">DGHI</a>) reported quarterly sales of $9.200 million which missed the analyst consensus estimate of $9.900 million by 7.07 percent. This is a 71.74 percent increase over sales of $5.357 million the same period last year.

Earnings Misses

DGHI

Digihost Technology Q3 Sales $9.200M Miss $9.900M Estimate

The termination of Walmart program agreement, effective May 21, 2024, increased the Domestic Card net charge-off rate by 39 basis points for October 2024. Excluding this impact, the Domestic Card net charge-off rate would have been 5.43%

Capital One Financial October Credit Card Domestic 30+ Day Performing Delinquencies Rate 4.61%, Net Charge-Offs Rate 5.82% - Filing

Redburn Atlantic analyst Simon Baker upgrades Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) from Neutral to Buy and announces $13 price target.

Upgrades

AUTL

Redburn Atlantic Upgrades Autolus Therapeutics to Buy, Announces $13 Price Target

ALHC

Alignment Healthcare Enters Into Privately Negotiated Subscription Agreements With Certain Investors, Pursuant To Which It Will Issue $330M Principal Amount Of 4.25% Convertible Senior Notes Due 2029

Scotiabank analyst George Farmer maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report) today and set a price target of $23.00. T...

Aura Biosciences Inc (AURA) Receives a Buy from Scotiabank

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xtant Medical Holdings (XTNT – Research Report), CVS...

Analysts' Top Healthcare Picks: Xtant Medical Holdings (XTNT), CVS Health (CVS)

Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value

"This is a transformative time for our Company, as we presented the first positive data in NMIBC, which we believe provides clinical evidence of th...

Aura Biosciences reports Q3 EPS (42c), consensus (44c)

Anshul Dhankher, an analyst from LifeSci Capital, maintained the Buy rating on Aura Biosciences Inc (AURA – Research Report). The associated price ...

Buy Rating for Aura Biosciences Inc Driven by Promising Clinical Progress and Strategic Growth

TD Cowen analyst Phil Nadeau has maintained their bullish stance on AURA stock, giving a Buy rating yesterday. Phil Nadeau's rating is based on sev...

Promising Developments and Financial Stability Justify Buy Rating for Aura Biosciences

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Aura Biosciences Inc (AURA – Research Report). The associated price tar...

Positive Outlook and Buy Rating for Aura Biosciences Inc Amid Promising Clinical Results and Financial Stability

Aura Biosciences Inc ( ($AURA) ) has released its Q3 earnings. Here is a breakdown of the information Aura Biosciences Inc presented to its investo...

Aura Biosciences Reports Q3 Financial Results

Analyst Julian Harrison of BTIG maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report), retaining the price target of $24.00. Jul...

Optimistic Buy Rating for Aura Biosciences Inc: Promising Trials and Strong Financials

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report), with a price ta...

AURA

XTNT

Press Releases

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Health Care

Aura Biosciences to Host Virtual KOL Event "Pioneering a New Standard of Care In Ocular Oncology" on May 29, 2024

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

General

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

Comments

Aura Biosciences

Aura Biosciences (AURA) Opzioni

Aura Biosciences (NASDAQ:AURA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO